Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

by Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S
Published 2018

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

by Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.
Published 2021

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

by Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.
Published 2020

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.

by Coles, Alasdair J, Arnold, Douglas L, Bass, Ann D, Boster, Aaron L, Compston, D Alastair S, Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H, Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C, Selmaj, Krzysztof W
Published 2021

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

by Coles, Alasdair J, Cohen, Jeffrey A, Fox, Edward J, Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W, Traboulsee, Anthony, Compston, D Alastair S, Margolin, David H, Thangavelu, Karthinathan, Chirieac, Madalina C, Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J, Panzara, Michael A, Arnold, Douglas L, CARE-MS II and CAMMS03409 Investigators
Published 2017

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

by Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Published 2021